Quantitative fragility of reported association between aspirin use and hepatocellular carcinoma risk in metabolic dysfunction-associated steatotic liver disease: Letter to the editor on "Aspirin and hepatocellular carcinoma risk in metabolic dysfunction-associated steatotic liver disease: Nationwide cohort study with genetic risk analysis".
- DOI
- 10.3350/cmh.2026.0282
- Published
- 2026 Nov 9
- Container
- Clinical and molecular hepatology
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.3350/cmh.2026.0282,
title = {Quantitative fragility of reported association between aspirin use and hepatocellular carcinoma risk in metabolic dysfunction-associated steatotic liver disease: Letter to the editor on "Aspirin and hepatocellular carcinoma risk in metabolic dysfunction-associated steatotic liver disease: Nationwide cohort study with genetic risk analysis".},
author = {Zhang SJ and Gao G},
year = {2026},
journal = {Clinical and molecular hepatology},
doi = {10.3350/cmh.2026.0282},
url = {https://doi.org/10.3350/cmh.2026.0282}
}RIS
TY - JOUR TI - Quantitative fragility of reported association between aspirin use and hepatocellular carcinoma risk in metabolic dysfunction-associated steatotic liver disease: Letter to the editor on "Aspirin and hepatocellular carcinoma risk in metabolic dysfunction-associated steatotic liver disease: Nationwide cohort study with genetic risk analysis". AU - Zhang SJ AU - Gao G PY - 2026 JO - Clinical and molecular hepatology DO - 10.3350/cmh.2026.0282 UR - https://doi.org/10.3350/cmh.2026.0282 ER -
APA
SJ, Z., & G, G. (2026). Quantitative fragility of reported association between aspirin use and hepatocellular carcinoma risk in metabolic dysfunction-associated steatotic liver disease: Letter to the editor on "Aspirin and hepatocellular carcinoma risk in metabolic dysfunction-associated steatotic liver disease: Nationwide cohort study with genetic risk analysis".. Clinical and molecular hepatology. https://doi.org/10.3350/cmh.2026.0282
Source records
- pubmed · retrieved 2026-11-10T13:27:17.080Z